NO20063478L - Noytraliserende epitopebasert vekstfremmende vaksine - Google Patents

Noytraliserende epitopebasert vekstfremmende vaksine

Info

Publication number
NO20063478L
NO20063478L NO20063478A NO20063478A NO20063478L NO 20063478 L NO20063478 L NO 20063478L NO 20063478 A NO20063478 A NO 20063478A NO 20063478 A NO20063478 A NO 20063478A NO 20063478 L NO20063478 L NO 20063478L
Authority
NO
Norway
Prior art keywords
peptides
gdf8
neutralizing epitope
based growth
fusion proteins
Prior art date
Application number
NO20063478A
Other languages
English (en)
Norwegian (no)
Inventor
David E Junker
Mark D Cochran
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34748944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20063478(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of NO20063478L publication Critical patent/NO20063478L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20063478A 2003-12-31 2006-07-28 Noytraliserende epitopebasert vekstfremmende vaksine NO20063478L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53371903P 2003-12-31 2003-12-31
PCT/US2004/043125 WO2005066204A2 (en) 2003-12-31 2004-12-21 Neutralizing epitope-based growth enhancing vaccine

Publications (1)

Publication Number Publication Date
NO20063478L true NO20063478L (no) 2006-08-28

Family

ID=34748944

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063478A NO20063478L (no) 2003-12-31 2006-07-28 Noytraliserende epitopebasert vekstfremmende vaksine

Country Status (21)

Country Link
US (3) US7371726B2 (pt)
EP (1) EP1699820A2 (pt)
JP (2) JP2007535912A (pt)
KR (1) KR20060120229A (pt)
CN (1) CN1902221A (pt)
AR (1) AR047345A1 (pt)
AU (1) AU2004312411B8 (pt)
BR (1) BRPI0418317A (pt)
CA (1) CA2551877A1 (pt)
EC (1) ECSP066683A (pt)
IL (1) IL176494A0 (pt)
MX (1) MXPA06007514A (pt)
NO (1) NO20063478L (pt)
NZ (1) NZ547593A (pt)
PE (1) PE20051050A1 (pt)
RU (1) RU2422460C2 (pt)
SG (1) SG153874A1 (pt)
TW (1) TWI357906B (pt)
UA (1) UA93855C2 (pt)
WO (1) WO2005066204A2 (pt)
ZA (1) ZA200605227B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US8426194B2 (en) * 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
EP1604011A4 (en) * 2003-01-21 2009-12-09 Ptc Therapeutics Inc METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE THE EXPRESSION OF DEPENDENT GENES FROM A NON-TRANSLATED REGION, AND METHODS OF USING SAME
US7371726B2 (en) * 2003-12-31 2008-05-13 Schering-Plough Animal Health Corporation Neutralizing GDF8 epitope-based growth enhancing vaccine
JP5335239B2 (ja) 2004-09-30 2013-11-06 マイオスティン・セラピューティクス・プロプライエタリー・リミテッド ミオスタチンアイソフォーム
WO2006073827A2 (en) * 2004-12-30 2006-07-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
JP5052517B2 (ja) * 2005-10-06 2012-10-17 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
BRPI0715072A2 (pt) * 2006-08-03 2013-06-25 Orico Ltd antagonistas de miostatina
AU2013231037B2 (en) * 2006-08-03 2016-05-12 Myostin Therapeutics Pty Ltd Myostatin antagonists
PT2066695E (pt) * 2006-09-05 2013-05-23 Lilly Co Eli Anticorpos anti-miostatina
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
UY33421A (es) * 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
SG10201506405YA (en) 2010-08-16 2015-10-29 Amgen Inc Polypeptides That Bind Myostatin, Compositions And Methods
SG10201509790YA (en) 2010-11-30 2015-12-30 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
JP6177249B2 (ja) 2011-11-14 2017-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
PL3816625T3 (pl) 2013-05-06 2026-01-26 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN112142844B (zh) 2015-02-05 2025-07-25 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
CN107771081A (zh) 2015-04-15 2018-03-06 瑞泽恩制药公司 用gdf8抑制剂增加力量和功能的方法
WO2017049011A1 (en) * 2015-09-15 2017-03-23 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
MX2018008369A (es) 2016-01-08 2019-05-15 Scholar Rock Inc Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
SMT202000598T1 (it) 2016-06-13 2021-01-05 Scholar Rock Inc Utilizzo di inibitori di miostatina e terapie combinate
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
ES2944357T3 (es) 2017-01-06 2023-06-20 Scholar Rock Inc Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina
MA52417A (fr) 2018-03-01 2021-01-06 Regeneron Pharma Procédés de modification de composition corporelle
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977438A (en) 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
CA2014033C (en) * 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
US5422110A (en) * 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
AU2699192A (en) * 1991-10-16 1993-05-21 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
EP1333035A3 (en) * 1993-03-19 2004-07-07 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US20030074680A1 (en) * 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
WO1998033887A1 (en) 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
AU746643B2 (en) * 1997-02-05 2002-05-02 Metamorphix International, Inc. Immunization against endogenous molecules
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
WO1999056768A1 (en) * 1998-05-06 1999-11-11 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
US6284882B1 (en) * 1999-06-10 2001-09-04 Abbott Laboratories Myostatin gene promoter and inhibition of activation thereof
SK722002A3 (en) * 1999-07-20 2003-02-04 Pharmexa As Method for down-regulating GDF-8 activity
AU4889100A (en) * 1999-07-30 2001-02-01 Pfizer Products Inc. Myostatin regulatory region, nucleotide sequence determination and methods for its use
WO2001026672A1 (en) 1999-10-13 2001-04-19 Roswell Park Memorial Institute Induction of a strong immune response to a self-tumor associated antigen
US6730306B1 (en) * 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
MXPA05006113A (es) 2002-12-11 2005-09-30 Pharmexa As Epitopos sencillos objetivo.
SI1581649T1 (sl) 2002-12-20 2011-09-30 Amgen Inc Vezna sredstva, ki zavirajo miostatin
US7371726B2 (en) * 2003-12-31 2008-05-13 Schering-Plough Animal Health Corporation Neutralizing GDF8 epitope-based growth enhancing vaccine
US20060281075A1 (en) * 2004-12-22 2006-12-14 Large Scale Biology Corporation Purification of viruses, proteins and nucleic acids
WO2006073827A2 (en) 2004-12-30 2006-07-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine

Also Published As

Publication number Publication date
BRPI0418317A (pt) 2007-05-02
JP2007535912A (ja) 2007-12-13
ZA200605227B (en) 2007-03-28
TW200526683A (en) 2005-08-16
US7585648B2 (en) 2009-09-08
US7892561B2 (en) 2011-02-22
CA2551877A1 (en) 2005-07-21
US20050143306A1 (en) 2005-06-30
CN1902221A (zh) 2007-01-24
EP1699820A2 (en) 2006-09-13
WO2005066204A3 (en) 2005-08-11
US7371726B2 (en) 2008-05-13
NZ547593A (en) 2009-09-25
AU2004312411B2 (en) 2011-11-03
AU2004312411B8 (en) 2011-11-24
AU2004312411A1 (en) 2005-07-21
US20080227156A1 (en) 2008-09-18
MXPA06007514A (es) 2006-08-31
TWI357906B (en) 2012-02-11
SG153874A1 (en) 2009-07-29
RU2006127314A (ru) 2008-02-10
WO2005066204A2 (en) 2005-07-21
PE20051050A1 (es) 2005-12-12
AR047345A1 (es) 2006-01-18
RU2422460C2 (ru) 2011-06-27
IL176494A0 (en) 2006-10-05
JP2011083290A (ja) 2011-04-28
UA93855C2 (ru) 2011-03-25
US20090311282A1 (en) 2009-12-17
KR20060120229A (ko) 2006-11-24
ECSP066683A (es) 2006-10-25

Similar Documents

Publication Publication Date Title
NO20063478L (no) Noytraliserende epitopebasert vekstfremmende vaksine
DK1355930T3 (da) Fremgangsmåde til identifikation, isolering og fremstilling af antigener mod et specifikt patogen
ATE528016T1 (de) Virusähnliche partikel als paramyxovirus- impfstoffe
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
ATE542829T1 (de) Impfstoff
NZ577828A (en) Human antibodies that bind human il-12 and methods for producing
DK1629011T3 (da) Humane anti-humane-DC3-bindingsmolekyler
NO20081043L (no) Vaksine for fisk
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
WO2002080851A3 (en) Chimeric vaccines
DK1780269T3 (da) Virusrensningsmetoder
DK1409692T3 (da) Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine
UA95329C2 (ru) Собачий тимусный стромальный лимфопоэтин и его применение
ATE348633T1 (de) Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
DE60037900D1 (de) Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
TW200510450A (en) Soluble fragments of the SARS-CoV spike glycoprotein
EP4291232A4 (en) Antibodies that bind metapneumovirus, antigenic metapneumovirus proteins, and uses thereof
NO20020615D0 (no) Vaksine
TW200634156A (en) Neutralizing epitope-based growth enhancing vaccine
GB2429711A (en) Heart and skeletal muscle inflammation (HSMI) virus
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
DK1227840T3 (da) Adjuverede, genetiske vacciner
Paoletti Recombinant avipox virus
EA200701031A1 (ru) Молекулы, способствующие гематопоэзу

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application